Chronic Kidney Disease Observational Cohort Study And Assessment Of Baseline Characteristics And Their Relationship With Diabetes Status And Kidney Function

Yıl 2023, Cilt: 4 Sayı: 1, 31 - 39, 31.01.2023

Sümeyra Koyuncu Koray Uludag Ali İhsan Günal

https://doi.org/10.47482/acmr.1142775

Öz

Background: Chronic kidney disease (CKD) may result in end-stage renal disease (ESRD), and undesirable outcomes such as death and dialysis. We carried out an observational cohort study to ascertain risk factors for the renal outcomes, all-cause mortality in patients with CKD. In this report, we studied the baseline demographic and laboratory characteristics of the cohort.
Methods: A single-center, retrospective, observational cohort study was conducted at the outpatient Nephrology Clinic of Health Sciences University, Kayseri Medical Faculty, from January 1, 2010, to December 31, 2020. Age 18 to 70 years and eGFR 15 to 59 mL/min/1.73 m2 were inclusion criteria. Baseline demographic and laboratory data were documented.
Results: One thousand seventy-three patients with CKD were enrolled in the study. Mean (SD) age was 55.87 (8.83) years, and 53.2% were men. %45.9 and %84.4 had diabetes mellitus and hypertension, respectively. The mean body mass index was 26.73 (3.95) kg/m2. Mean eGFR was 34.14 (10.45) mL/min/1.73 m2 using chronic kidney disease epidemiology collaboration. Median (p25-p75) urinary protein-creatinine ratio was 48.80 [22.40, 89.00] mg/mmol. Older patients had a lower eGFR, and the male gender was more common at stage 3 patients. Stage 4 patients had lower hemoglobin and serum calcium levels. Also, low eGFR was associated with high uric acid levels.
Conclusion: This study along with future analysis may elucidate the natural history and clinical consequences of CKD. Controllable factors could be understood, and CKD progression and adverse outcomes may be prevented in this way.

Anahtar Kelimeler

chronic kdney disease, diabetes, hypertension, renal outcomes

Kaynakça

• References 1. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020; 395: 709-33
• 2. Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008; 31: 1101-07
• 3. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013; 382: 339-52
• 4. Li L, Astor BC, Lewis J, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012; 59: 504-12
• 5. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011; 79: 1331-40
• 6. Rucker D, Hemmelgarn BR, Lin M, et al. Quality of care and mortality are worse in chronic kidney disease patients living in remote areas. Kidney Int. 2011; 79: 210-17
• 7. Weiner DE, Krassilnikova M, Tighiouart H, Salem DN, Levey AS and Sarnak MJ. CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study. BMC Nephrol. 2009; 10: 26
• 8. Abboud H and Henrich WL. Clinical practice. Stage IV chronic kidney disease. N Engl J Med. 2010; 362: 56-65
• 9. Drury PL, Ting R, Zannino D, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011; 54: 32-43
• 10. Iimori S, Naito S, Noda Y, et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Nephrology (Carlton). 2015; 20: 601-08
• 11. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305
• 12. Shah R, Matthews GJ, Shah RY, et al. Serum Fractalkine (CX3CL1) and Cardiovascular Outcomes and Diabetes: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2015; 66: 266-73
• 13. Shoji T, Emoto M, Shinohara K, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol. 2001; 12: 2117-24 (doi: 10.1681/ASN.V12102117).
• 14. Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol. 2009; 4: 1302-11
• 15. Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol. 2010; 14: 558-70
• 16. Martínez-Castelao A, Górriz JL, Portolés JM, et al. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. BMC Nephrol. 2011; 12: 53
• 17. Titze S, Schmid M, Köttgen A, et al. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant. 2015; 30: 441-51
• 18. Kang E, Han M, Kim H, et al. Baseline General Characteristics of the Korean Chronic Kidney Disease: Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD). J Korean Med Sci. 2017; 32: 221-30
• 19. Imai E, Horio M, Iseki K, et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol. 2007; 11: 156-63
• 20. Fryar CD, Ostchega Y, Hales CM, Zhang G and Kruszon-Moran D. Hypertension Prevalence and Control Among Adults: United States, 2015-2016. NCHS Data Brief. 2017: 1-8.
• 21. National Diabetes Statistics Report, 2020, Centers for Disease Control and Prevention, Atlanta, GA:Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2020.
• 22. Hsu C-Y, McCulloch CE, Iribarren C, Darbinian J and Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144: 21-28
• 23. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42: 1050-65
• 24. Brenner BM, Cooper ME, Zeeuw D de, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-69
• 25. Nicola L de, Minutolo R, Chiodini P, et al. Global approach to cardiovascular risk in chronic kidney disease: reality and opportunities for intervention. Kidney Int. 2006; 69: 538-45
• 26. Jankowski J, Floege J, Fliser D, Böhm M and Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021; 143: 1157-72
• 27. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43: S1-290.
• 28. Duru OK, Li S, Jurkovitz C, et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis. 2008; 51: 192-98
• 29. Agarwal R. Debate: CON Position. People with chronic kidney disease should have a blood pressure lower than 130/80 mm Hg. Am J Nephrol. 2010; 32: 374-6; discussion 377-8
• 30. Appel LJ, Wright JT, Greene T, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010; 363: 918-29